Biopharma must pair innovation with operational readiness to scale therapies

The article argues that breakthrough science alone no longer guarantees success in biopharma. Companies now face pressure to turn discoveries into reliably manufactured, delivered, and scalable products.

Operational challenges such as manufacturing delays, CDMO bottlenecks, workforce shortages, and supply‑chain instability are identified as key friction points that can slow patient access to new therapies.

The piece stresses that without strong industrial capabilities-manufacturing readiness, a skilled workforce, and resilient supply chains-promising drugs cannot generate value, even if they are scientifically advanced.

For leaders, building operational readiness is becoming a strategic priority alongside traditional R&D focus, as the industry moves toward more specialized therapies and complex production processes.